CClinicalTrials.gg
Sign In
Not yet recruitingNCT06495879Updated Jul 11, 2024

Association Between Triglyceride Glucose Index and Severity of Coronary Artery Disease

An observational study in Coronary Artery Disease, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Coronary artery disease (CAD) is a chronic cardiovascular disease occurring due to atherosclerotic occlusion of the coronary arteries (1).

Acute coronary syndrome (ACS) is the most severe type of Coronary artery disease including unstable angina(UA) , St -elevation myocardial infarction (STEMI) Non ST elevation mayocardial infarction (NSTEMI) (2).

Despite the use of current guidline-recommended therapeutics including Percutaneous coronary intervention (PCI) or coronary Artery bypass Grafting (CABG) and optimal drug treatments some patients with ischemic heart disease (IHD) remain at high risk for recurrent Cardio vascular events(3).

Triglyceride glucose index (TYG) has a good potential in predicting poor cardiovascular prognosis in patients with IHD (4).

02

Conditions studied

  • Coronary Artery Disease
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's planned enrollment of 100 is below the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will be conducted on patients investigated for IHD by coronary angiography at coronary catheterization unit at sohag university hospital

Exclusion Criteria:

Inclusion criteria

  • This study will be conducted on patients investigated for IHD by coronary angiography at coronary catheterization unit at sohag university hospital

Exclusion criteria

Exclusion Criteria:

  • 1- Patients younger than 18 years. 2- Patients with malignant tumor disease . 3- Patients with infectious or sever liver or kidney disease . 4- Patients lacked data on HbA1c,FPG,TG.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Triglyceride glucose index

    Association between Triglyceride glucose index and severity of coronary artery disease

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27. PubMed 33501848 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012 Oct 16;126(16):2020-35. doi: 10.1161/CIR.0b013e31826e1058. Epub 2012 Aug 24. No abstract available. PubMed 22923432 ↗
  • Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tunon J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum In: Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. doi: 10.1016/S2213-8587(19)30242-6. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21. doi: 10.1016/S2213-8587(19)30259-1. PubMed 31272931 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06495879
Lead sponsor
Sohag University
Responsible party
Fatma Mohamed Abdelaal (Fatma Mohamed Abdelal, Sohag University) — Principal investigator
First posted
Jul 11, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Jul 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Disease→

Other studies from this sponsor

Sohag University

Start the discussion